Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

Sarah Harris, Giancarlo Comi, Bruce A. C. Cree, Douglas L. Arnold, Lawrence Steinman, James K. Sheffield, Harry Southworth, Ludwig Kappos, Jeffrey A. Cohen, Unknown

Open source

DOI
10.1111/ene.15009
Published
2021-08-23
Container
European Journal of Neurology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/ene.15009,
  title = {Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials},
  author = {Sarah Harris and Giancarlo Comi and Bruce A. C. Cree and Douglas L. Arnold and Lawrence Steinman and James K. Sheffield and Harry Southworth and Ludwig Kappos and Jeffrey A. Cohen and Unknown},
  year = {2021},
  journal = {European Journal of Neurology},
  doi = {10.1111/ene.15009},
  url = {https://doi.org/10.1111/ene.15009}
}

RIS

TY  - JOUR
TI  - Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
AU  - Sarah Harris
AU  - Giancarlo Comi
AU  - Bruce A. C. Cree
AU  - Douglas L. Arnold
AU  - Lawrence Steinman
AU  - James K. Sheffield
AU  - Harry Southworth
AU  - Ludwig Kappos
AU  - Jeffrey A. Cohen
AU  - Unknown
PY  - 2021
JO  - European Journal of Neurology
DO  - 10.1111/ene.15009
UR  - https://doi.org/10.1111/ene.15009
ER  - 

APA

Harris, S., Comi, G., Cree, B. A. C., Arnold, D. L., Steinman, L., Sheffield, J. K., Southworth, H., Kappos, L., Cohen, J. A., & Unknown (2021). Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. European Journal of Neurology. https://doi.org/10.1111/ene.15009

Source records